DKSH has acquired the rights for Rocephin® from Roche across more than 80 markets. Following the acquisition of Meliane® from Bayer announced in July, this transaction is a further step in DKSH’s strategy to expand its Healthcare Own Brands portfolio and strengthen its presence in higher-value segments.

 

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.